Compare ADMA Biologics Inc (ADMA) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Yum China Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.3 (market cap $2.13B), while Yum China Holdings Inc trades at $42.83 (market cap $14.58B). The key difference: Yum China Holdings Inc is far larger — about 6.8× ADMA Biologics Inc's market cap, and Yum China Holdings Inc pays a 2.75% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | YUMC | |
|---|---|---|
Market Cap | $2.13B | $14.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $57.95 |
52-Week Low | $7.60 | $40.18 |
Enterprise Value | $2.20B | $15.47B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
YUMC trades at $42.22, up 1.25% today, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.87 exceeding the $0.854 estimate. Revenue grew to $11.80B in 2025, and the stock trades at a P/E of 16.28. Recent news highlights YUMC's acquisition of Pizza Hut brand rights in mainland China and a $512 million share repurchase plan.
The outlook is positive given consistent earnings outperformance, strategic brand control expansion, and shareholder returns. Risks include China's competitive consumer market and economic sensitivity. Analyst consensus is strongly bullish with 14 buys and no sells, supporting a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
